Fetal BPA Exposure Could Cause Estrogen-Related Diseases: Study

Amid growing concerns over health risks posed by traces of the chemical bisphenol-A (BPA) in the nation’s food supply, a new study indicates that exposure to the chemical in utero may change how the body regulates estrogen, potentially increasing the risk of hormonal problems. 

In a study published in the FASEB Journal on June 16, researchers from Yale University determined that exposing mice to bisphenol-A (BPA) before birth changed the estrogen response in more than 1,000 genes in the uterine epigenome of the exposed mice, raising concerns that the chemical could cause estrogen-related diseases in humans.

Bisphenol-A, or BPA, is chemical commonly used to manufacture plastic products, as well as aluminum can liners. The chemical is ubiquitous in America and found in many products, including canned foods, drink bottles, toys, car seats and more.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The study involved exposing pregnant mice to environmentally relevant doses of BPA and comparing them to a control group that was not exposed. Uterine DNA and RNA were then examined.

Researchers found that mice exposed to BPA had permanently altered genes resulting in changes in gene expression in more than 1,000 genes.

In the new study, the affected genes that are regulated by estrogen and are implicated in the formation of estrogen-related disease, include infertility, endometriosis, endometrial cancer, osteoporosis, prostate cancer, neurodegenerative disease, obesity and breast cancer.

Researchers said the majority of genes that showed altered expression affect estrogen response after puberty. Changes to the uterus are often not present at birth after in utero exposure to BPA or in early life, however, changes become apparent after sexual maturity.

“Gene–environment interactions driven by early life xenoestrogen exposure likely contributes to increased risk of estrogen-related disease in adults,” the study’s authors concluded.

Concerns regarding BPA have been renewed over the years as exposure in utero has been linked to female reproductive disorders, endometrial hyperplasia and breast cancer.

A study published in FASEB Journal in 2014 linked in utero BPA exposure to increased risk of food intolerances during infancy, even at levels lower than current safety limits.

Another study published in 2014 concluded prenatal exposure to BPA may raise a child’s likelihood of experiencing breathing problems by the age of five. The higher the urinary concentration of BPA during pregnancy, the greater the risk of wheezing for the child.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California
Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California (Posted 2 days ago)

A growing number of lawsuits against generic Depo-Provera manufacturers have been filed throughout the federal court system, each alleging that women were not adequately warned about the risk of meningioma brain tumors from the birth control shot.

Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024
Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024 (Posted 3 days ago)

Former users of the recalled sickle cell disease drug Oxbryta have filed a class action lawsuit, claiming the manufacturer failed to warn consumers about risks associated with the medication, which can result in stroke and death.